AzTrials
AzTrials

Sepsis and Septic ShockNCT02750163

Circulating Free Hemoglobin and Microcirculation After Administration of Paracetamol in Febrile Septic Patient

An observational study of Sepsis and Septic Shock, run by Università Politecnica delle Marche at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate the effect of Acetaminophen on the main parameters of microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on the expression of PD1/Pd-L1, in pyrexial septic patient. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Sepsis and Septic Shock
What is being tested?
paracetamol
How many people
50 participants
Where
1 siteItaly
Study dates
5 Jul 2017to 5 Jun 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 50 patients with sepsis or septic shock

Who may be able to join

  • Patients with sepsis, severe sepsis and septic shock with high body temperature that need administration of Paracetamol and which have previously monitored blood pressure and have a central venous catheter in place.

Who cannot join

  • age < 18 years
  • pregnancy
  • hemodialysis
  • hemolysis of the blood sample
  • use of Paracetamol in the previous 12 hours
  • conditions that do not allow the possibility of getting a monitoring of sublingual microcirculation (maxillofacial trauma, serious inability to jaw, copious blood loss or secretions from the mouth)

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • AOU Ospedali Riuniti Ancona - Università Politecnica delle Marche

    Ancona, 60126

Other trials in Italy

About this study

The aim of this study is to evaluate the effect of Acetaminophen on the main parameters of microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on the expression of PD1/Pd-L1, in pyrexial septic patient.

Read the detailed description

It has been established that plasma levels of extra-cellular free hemoglobin increased significantly in patients with certain disease, including sickle cellular disease, or undergoing invasive treatments, like coronary bypass surgery, blood transfusions and hemodialysis.

In all these conditions, high levels of free hemoglobin were associated with poor outcome and with serious complications such as acute renal failure and myocardial infarction.

In the animal model of sepsis, increased values of plasma free hemoglobin has been related to increased mortality, especially if a concomitant lack of haptoglobin and hemopexin coexists.

It is likely that the release of free hemoglobin in the blood of septic patient is attributable to changes in the membrane of red blood cells.

These changes have been recognized in humans as a source of damage of the vascular endothelium and consumption of free radical scavenger systems.

It has been hypothesized that the extracellular hemoglobin, when the protective mechanism have been saturated, causes - trough reaction with NO - the formation of nitrate and lipids peroxidation and boosts the immune response mediated by the monocyte -macrophage system.

It is also liable for a condition of endothelial dysfunction and NO resistance that could impair the microcirculation.

Our previous work showed that higher levels of free hemoglobin resulted in a significant reduction in the density of the microcirculation in septic patients undergoing blood transfusions.

On animal model Paracetamol (or acetaminophen), drug commonly used for its analgesic and antipyretic effects, demonstrated strong efficacy in preventing oxidative damage and protection of renal damage in the context of increased levels of plasma free hemoglobin (as in Rhabdomyolysis and myoglobulinemie).

This effect is attributed to the ability of the Paracetamol to cross react with either nitric oxide synthase (NOS) by increasing the synthesis of NO, and with cyclooxygenase (COX), by inhibiting the synthesis of prostaglandin I2 (PGI2-antiplatelet and vasodilator effect) without interfering with the production of Thromboxane A2 (TXA2-powerful vasoconstrictor and pro-thrombogenic) causing an imbalance of endovascular homeostasis.

The increased oxidative stress produced by sepsis is also responsible of glycocalix damage, the thin layer that lines the surface of endothelium in contact with the blood and increased the free hemoglobin.

ROS are also responsible to up-regulation of Programmed Death-1 related molecules (PD-1/PD-L1) that render T cells susceptible to inhibitory modulation, inability to proliferate and reduced capacity to clear bacteria, inducing "immunosuppression" and more difficult recovery from septic shock. PD-1/PD-L1 system has been recently studied as potential predictor of mortality and active player in resolution of sepsis-induced Acute Lung Injury.

Finally, a recent study on septic patient showed an increased mortality in people with elevated values of free hemoglobin versus patients without this increase, and the efficacy of of Paracetamol to reduce the concentration of F2- isoprostane (marker of oxidative stress), associated with lower risk of death.

This effect was lost in the cohort of septic patients without free hemoglobin registered.

Aim of this study is to evaluate the effect of paracetamol administration on the microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on the expression of PD1/Pd-L1, in pyrexial septic patient. Paracetamol is given only on the basis of a clinical indication, not because of the study and in our institution paracetamol is the drug of choice to treat fever.

When there are inclusion criteria (febrile septic patient) and no exclusion criteria, and patient is going to receive paracetamol, informed consent will be taken. When the neurological conditions do not permit, relatives will be informed and the patients will still included in the protocol. The informed consent will be taken when the patient clinical condition permits it.

Before the administration of the drug, at the end of infusion and after 30 minutes after infusion, the main parameters of the sublingual microcirculation will be monitored, using the the incident dark field imaging technique (IDF), including an assessment of glycocalyx, Near InfraRed (NIRS) parameters with the vascular occlusion test (VOT), vital signs and the dosage of any infusion of vasoactive drug.

Demographic and clinical records will be collected at T0 and T1. Acute lung injury will be investigated through gas analytical and laboratory data at the same timepoints.

Arterial blood samples will be collected at T0 and 2 hours after the infusion of Acetaminophen (that will represent T2). Blood will be immediately centrifuged and plasma and serum samples will be stored at -70°C for subsequent analysis. We will measure: fHb levels, markers of oxidative damage (F2-isoprastane and F2-isoflurane), of endothelial cell injury (endothelin-1) and glycocalyx damage (sindecan-1, heparasulfate), PD-1/PD-L1.

Being tested
paracetamol
Medical subject headings
Sepsis, Shock, Septic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • paracetamolDrug

    Paracetamol will be given to febrile septic patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Perfused Vessel Density (PVD)

    The perfused vessel density (PVD), unit of measure mm/mm2, is detected in vivo by Incident Dark Field Imaging at sublingual microcirculation. It represents the quantity of well perfused vessels at microcirculatory level.

    Measured: 30 minutes

Secondary outcomes (2)
  1. StO2 upload

    StO2 upslope (%/min) is measured with Near InfraRed Spectroscopy at the tenar muscle. It represents the velocity of the recovery of the tissue oxygen saturation after a short period of ischemia of the hand, the Vascular Occlusion Test.

    Measured: 30 minutes

  2. Microcirculatory flow index (MFI)

    Microcirculatory Flow Index detected in vivo by Incident Dark Field Imaging at sublingual microcirculation. It represents the quality of blood flow at microcirculatory level.

    Measured: 30 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2016 (estimated)
  2. Study start5 Jul 2017
  3. Primary completion5 Jun 2019
  4. Study completion5 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02750163
Sponsor's protocol ID
FreeHb
Status last verified
Apr 2019
First submitted
16 Apr 2016
Last updated
18 Jul 2019
Results posted
No
Data monitoring committee
No

Publications

  • Scorcella C, Domizi R, Amoroso S, Carsetti A, Casarotta E, Castaldo P, D'angelo C, Damiani E, Gasparri F, Donati A, Adrario E. Pharmacogenetics in critical care: association between CYP3A5 rs776746 A/G genotype and acetaminophen response in sepsis and septic shock. BMC Anesthesiol. 2023 Feb 16;23(1):55. doi: 10.1186/s12871-023-02018-y.

    PubMed 36797680

Questions about this trial

What is this clinical trial studying?

An observational study of Sepsis and Septic Shock, run by Università Politecnica delle Marche at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Perfused Vessel Density (PVD) (time frame: 30 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02750163, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in